RESEARCH ARTICLE

The landscape of N¹-methyladenosine (m¹A) modification in mRNA of the decidua in severe preeclampsia

Jing Tong 1,2, Hua Li 3, Liang Zhang 4, and Cong Zhang 1,2,5,6*

Recent discoveries in mRNA modification have highlighted N¹-methyladenosine (m¹A), but its role in preeclampsia (PE) pathogenesis remains unclear. In this study, we utilized methylated RNA immunoprecipitation sequencing (MeRIP-seq) and RNA sequencing (RNA-seq) to identify m¹A peaks and the expression profile of mRNA in the decidua of humans with early-onset PE (EPE), late-onset PE (LPE), and normal pregnancy (NP). We assessed the m¹A modification patterns in preeclamptic decidua using 10 m¹A modulators. Our bioinformatic analysis focused on differentially methylated mRNAs (DMGs) and differentially expressed mRNAs (DEGs) in pairwise comparisons of EPE vs NP, LPE vs NP, and EPE vs LPE, as well as m¹A-related DEGs. The comparisons of EPE vs NP, LPE vs NP, and EPE vs LPE, as well as m¹A-related DEGs. The comparisons of EPE vs NP, LPE vs NP, and EPE vs LPE, as well as m¹A-related DEGs. The comparisons of EPE vs NP, LPE vs NP, and EPE vs LPE, as well as m¹A-related DEGs. The comparisons of EPE vs NP, LPE vs NP, and EPE vs LPE, as well as m¹A-related DEGs. The comparisons of EPE vs NP, LPE vs NP, and EPE vs LPE, as well as m¹A-related DEGs. The comparisons of EPE vs NP, LPE vs NP, and EPE vs LPE, as well as m¹A-related DEGs. The comparisons of EPE vs NP, LPE vs NP, and EPE vs LPE identified 3110, 2801, and 2818 DMGs, respectively. We discerned three different m¹A modification patterns from this data. Further analysis revealed that key PE-related DMGs and m¹A-related DEGs predominantly influence signaling pathways critical for decidualization, including cAMP, MAPK, PI3K-Akt, Notch, and TGF-β pathways. Additionally, these modifications impact pathways related to vascular smooth muscle contraction, estrogen signaling, and relaxin signaling, contributing to vascular dysfunction. Our findings demonstrate that preeclamptic decidua exhibits unique mRNA m¹A modification patterns and gene expression profiles that significantly alter signaling pathways essential for both decidualization and vascul

Keywords: Decidua, decidualization, N¹-methyladenosine (m¹A), methylated RNA immunoprecipitation sequencing (MeRIP-seq), preeclampsia (PE), vascular dysfunction.

Introduction

Preeclampsia (PE) is a multisystem syndrome that uniquely occurs during human pregnancy. It is characterized by the new onset of hypertension, proteinuria, and other signs of maternal vascular damage after 20 weeks of gestation. PE affects approximately 8% of first-time pregnancies worldwide each year, impacting eight million mother-infant pairs. It is recognized as one of the leading causes of maternal and perinatal morbidity and mortality [1, 2]. Severe PE (sPE) is diagnosed based on a further elevation of systolic pressure \geq 160 mm Hg or diastolic pressure \geq 110 mm Hg, or any of the following: thrombocytopenia, impaired liver function, progressive renal insufficiency, pulmonary edema, and the new onset of cerebral or visual disturbances [3].

Currently, the etiology of PE remains unclear, but dysregulated decidualization has been a subject of interest in studying the genesis of PE. Previous studies have confirmed and augmented the results through global transcriptional profiling of decidua in sPE [4]. It was surprising to find that the decidual gene transcription profile was altered in sPE. Additionally, decidual cells from patients with sPE, when dedifferentiated in vitro, failed to redecidualize in culture [5]. Therefore, the decidua is considered a prime candidate for the genesis of PE [6]. In humans, decidualization, the formation of the decidua, is independent of the presence of a conceptus. It is a progressive process that involves hormonally regulated differentiation of human endometrial stromal cells (ESCs), morphologically transforming into enlarged round-shaped cells from a fibroblast-like population driven by genetic reprogramming [7].

 N^1 -methyladenosine (m¹A) is a recently identified mRNA modification that is found enriched around the first codon upstream of the first splice site and alternative translation initiation sites. This modification is highly conserved in human cells and is responsive to physiological conditions. It correlates positively with protein production, indicating a functional

¹Department of Reproductive Medicine, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; ²Shanghai Key Laboratory for Assisted Reproduction and Reproductive Genetics, Shanghai, China; ³Jinan Maternal and Child Health Care Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China; ⁴Research Center of Translational Medicine, Jinan Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China; ⁵Shandong Provincial Key Laboratory of Animal Resistance Biology, College of Life Sciences, Shandong Normal University, Jinan, Shandong, China; ⁶Shandong Provincial Key Laboratory of Reproductive Medicine, Jinan, Shandong, China:

^{*}Correspondence to Cong Zhang: zhangxinyunlife@163.com

Associate Editor: Yan Sun

DOI: 10.17305/bb.2024.10532

^{© 2024} Tong et al. This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).

role in promoting translation of methylated mRNA [8]. m¹A modification is modified by the m¹A methyltransferases, or "writers", such as *TRMTIOC*, *TRMT61B*, *TRMT6*, and *TRMT61A*, and removed by the demethylases, or "erasers" including *ALKBH1* and *ALKBH3*. It is recognized by m¹A-binding proteins *YTHDF1*, *YTHDF2*, *YTHDF3*, and *YTHDC1*, also known as "readers" [9, 10]. These ten regulatory genes play an essential role in the process of modifying m¹A. However, little is known about the precise location and biogenesis of m¹A methylation in mRNA of decidual tissue in sPE.

To reveal mechanisms in decidualization and explore potential epigenetic biomarkers in sPE, this study aimed to investigate the m¹A methylation atlas in mRNA in decidual tissue. Two strategies were employed: (i) an m¹A-specific and in-depth bioinformatics analysis of m¹A in mRNA obtained from individuals with sPE and normal pregnancies (NPs) using methylated RNA immunoprecipitation sequencing (MeRIP-seq) and (ii) an analysis of m¹A modification patterns by RNA sequencing (RNA-seq) in decidual tissue of sPE and NPs.

Materials and methods

Participants and samples

Nine decidua samples were collected from patients with an NP (n = 3), EPE (n = 3), and LPE (n = 3) at the Department of Obstetrics and Gynecology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, between January 2018 and July 2019. EPE was defined as the onset of symptoms before 34 weeks of gestation, while LPE was defined as the onset of symptoms at or after 34 weeks of gestation [3]. Patients with multiple pregnancies and other complications, such as maternal diabetes, thyroid dysfunction, and abnormal placental structure were excluded. Human decidua basalis was collected from the placental bed during caesarean section, separated into centrifuge tubes, and snap-frozen in liquid nitrogen for further analysis.

MeRIP-seq and RNA-seq

MeRIP-Seq was performed as described in the published procedure with slight modifications [11]. Total RNA was isolated using Trizol Reagent (Life Technologies) and then quantified using the NanoDrop ND-1000 instrument (Thermo Fisher Scientific, MA, USA). The RNA purity was assessed by ensuring that its OD260/OD280 value fell between 1.8 and 2.1. Next, the total RNA was depleted of rRNA using Ribo-zero (Illumina) and fragmented using an RNA fragmentation reagent (Thermo Fisher Scientific). All of the RNA fragments were subjected to immunoprecipitation using the GenSeqTM m¹A-MeRIP Kit (GenSeq Inc., China), following the manufacturer's instructions. The input samples, which underwent no immunoprecipitation, were used to generate RNA-seq libraries. Both the input and immunoprecipitation samples were used to construct libraries using the NEBNext® Ultra II Directional RNA Library Prep Kit (New England Biolabs, Inc., USA). The libraries were then sequenced on a HiSeq platform (Illumina).

Sequencing data analysis

Paired-end reads were obtained from the Illumina HiSeq 4000 sequencer and underwent quality control using Q30.

Clean reads were then generated after trimming the 3' adaptors and removing low-quality reads using the Cutadapt software (v1.9.3). These clean reads from all libraries were aligned to the UCSC HG19 reference genome using the Hisat2 software. For the m¹A IP-seq data, the MACS software was utilized to identify methylated sites on RNAs (peaks) [12]. Differential methylated sites were determined using the DiffReps software [13]. Custom scripts were developed to select the peaks that overlapped with mRNA exons [14]. The mRNAs that overlapped with these differentially methylated peaks and had a fold change (FC) of at least 2.0 (Log (FC) \geq 1.0) and a P value less than or equal to 0.0001 were classified as differentially methylated mRNAs (DMGs). For the input-seq data, raw counts were obtained using the HTSeq software (v0.9.1) and normalized using EdgeR [15]. The differentially expressed mRNAs (DEGs) were defined as those with an FC of at least 2.0 (Log (FC) \geq 1.0) and a P value less than or equal to 0.01.

Bioinformatics analysis

Consensus clustering analysis was performed based on the expression of 10 m¹A regulators using the Consensus Cluster Plus R package. We employed the consensus cumulative distribution function (CDF) and the delta area plot to evaluate cluster stability and robustness. Based on these criteria, we found that a value of K = 3 yielded the most stable and interpretable clustering solution. Consequently, the PE group was divided into three distinct clusters. Gene set variation analysis (GSVA) was then performed in the PE and NP groups using the GSVA package in R package. The gene sets for GSVA were obtained from the MSigDB database, specifically the "C2.cp. kegg. V 7.5.1. symbols" gene sets (accessed on 8 May 2022). The m¹A-related DEGs were defined as the union of genes selected in m¹A modification pattern pairwise comparisons, meeting the criteria of an FC of \geq 2.0 $(Log(FC) \ge 1.0)$ with adjusted P values of <0.05. UpSetR was used for data exploration and generating set visualizations [16]. The DMGs, DEGs, and m¹A-related DEGs were then subjected to functional and pathway enrichment analysis using the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases. GO, the world's largest source of information on the functions of genes (www.geneontology.org), and KEGG (www.genome.jp/kegg) provide insights into the high-level functions and utilities of biological systems, respectively.

External validation of the mRNA expression of key $\rm m^1A\mathchar`elated$ DEGs and $\rm m^1A$ modulators

We selected a validation set consisting of gene expression data from 60 preeclamptic patients and 65 normal controls sourced from the Gene Expression Omnibus (GEO) dataset, specifically GSE60438. To normalize the gene expression data, we employed the "Scale" function, which facilitated subsequent comparative analyses.

Ethical statement

The study was approved by the Ren Ji Hospital Research and Ethics Committee. All participants provided informed consent before the caesarean section.




Figure 1. The overview of the m¹A methylation map in pairwise comparisons. (A–C) The total number of unique and common methylated m¹A peaks in EPE vs NP (A, upper section), LPE vs NP (B, upper section), and EPE vs LPE (C, upper section) comparisons; while the lower sections show the total number of unique, common, and non-m¹A methylated mRNAs in EPE vs NP (A), LPE vs NP (B), and EPE vs LPE (C) comparisons; (D–F) The distribution of differentially methylated m¹A sites with significance across chromosomes for three comparisons. From up to down are EPE vs NP (D), LPE vs NP (E), and EPE vs LPE (F). EPE: Early-onset preeclampsia; LPE: Late-onset preeclampsia; NP: Normal pregnancy.

Statistical analysis

Statistical analyses and visualizations were conducted using R software (version 3.5.3, https://www.r-project.org/) and GraphPad Prism v6.0 for Mac (GraphPad; San Diego, CA, USA). The Student's *t*-test was employed to assess the statistical differences between the two groups. For all analyses, a two-sided *P* value was utilized, with a significance level set at P < 0.05.

Results

Overview of the m¹A methylation map in pairwise comparisons The pairwise comparison of m¹A peaks and m¹A methylated mRNAs in the three groups, EPE vs NP, LPE vs NP, and EPE vs LPE, revealed unique m¹A peaks and unique m¹A methylated mRNAs in each comparison. In the EPE group, a total of 6767 unique m¹A peaks and 1659 unique m¹A methylated mRNAs were identified. Similarly, in the NP group, there were 7429 unique m¹A peaks and 1718 unique m¹A methylated mRNAs in the EPE vs NP comparison (Figure 1A). In the LPE group, there were 5966 unique m¹A peaks and 1510 unique m¹A methylated mRNAs; and 8648 unique m¹A peaks and 2159 unique m¹A methylated mRNAs in the NP group in the LPE vs NP comparison (Figure 1B). Further, a total of 8184 unique m¹A peaks and 2157 unique m¹A methylated mRNAs were obtained in the EPE group; and 6162 unique m¹A peaks and 1567 unique m¹A methylated mRNAs in the LPE group for the EPE vs LPE comparison (Figure 1C). Subsequently, all the differentiated methylated m¹A peaks in each comparison were mapped to human




Figure 2. **GO** and pathway analysis of key preeclampsia-related DMGs. (A) Venn diagram depicts the overlapping regions; (B) The top ten significant pathways; (C) A bar plot was generated for the top ten GO terms with the most significant *P* values for biological processes (C1), cellular component (C2), and molecular function (C3). The data shown are the negative log₁₀ (*P* value) within each category. EPE: Early-onset preeclampsia; LPE: Late-onset preeclampsia; NP: Normal pregnancy; GO: Gene ontology.

chromosomes. They were distributed across all chromosomes, with higher abundance observed in chr1, chr17, and chr19, while no $m^{1}A$ peaks were found in chrY (Figure 1D–1F).

GO and KEGG pathway analysis of DMGs

A comparison of EPE vs NP, LPE vs NP, and EPE vs LPE resulted in 3110, 2801, and 2818 DMGs, respectively. Table 1 presents the top 20 DMGs identified in the pairwise comparisons. To determine the biological significance of m¹A modifications in preeclamptic decidua, GO and KEGG pathway analyses were conducted for the DMGs (Figures S1–S4). The GO analysis was divided into three functional groups: biological process (BP), cellular component (CC), and molecular function (MF).

To account for the bias caused by non-matched gestation age in the PE cases and NP controls, a Venn diagram was utilized to visualize the overlaps between the pairwise comparisons [17]. A total of 526 overlapping DMGs were identified as the key PE-related DMGs (Figure 2A). Additionally, KEGG pathway and GO analyses were performed to further elucidate the influence of these key PE-related DMGs. Figure 2B displays the top ten significantly enriched KEGG pathways (P < 0.01), including calcium signaling pathway, phosphatidylinositol signaling system, axon guidance, protein digestion and absorption, and others. The enriched GO terms, arranged according to BP, CC, and MF, are shown in Figure 2C1-2C3 (P < 0.001). The enriched BPs mainly include cell morphogenesis involved in neuron differentiation, regulation of small GTPase-mediated signal transduction, and regulation of Ras protein signal transduction, among others. In terms of CC annotation classification, the key PE-related DMGs are mainly associated with adherens junctions, extracellular matrix, and actin cytoskeleton, among others. Regarding MF, the key PE-related DMGs are mainly localized in actin binding, GTPase activator activity, and signaling adaptor activity, among others.

Consensus clustering and GSVA of m¹A regulators

Based on the expression levels of $m^{1}A$ regulators, consensus clustering analysis was performed. K = 3 was determined to be the optimal selection for dividing PE patients into three clusters: cluster A, cluster B, and cluster C (Figure 3A). Figure 3B shows the expression of 10 m¹A methylation regulators between EPE and LPE decidua. Compared to EPE, the expression of ALKBH3 was significantly lower in LPE decidua, while the expression of YTHDF1 was significantly higher.

Subsequently, GSVA enrichment analysis of the three m¹A modification patterns was conducted to investigate the associated pathways and biological significance. Figure 3C shows that m¹A cluster A is significantly enriched in amino sugar

Table 1. Top 20 differentially methylated m¹A peaks in pairwise comparisons

Comparison	Chromosome	Peak start	Peak end	Gene name	m ¹ A methylation	Fold change	P value
EPE vs NP	6	32485153	32485320	HLA-DRB	hyper	540.1	0.0000
	3	50197007	50197167	SEMA3F	hypo	281.2	0.0000
	4	183245098	183245260	TENM3	hyper	76.84	0.0000
	19	49560377	49561120	CGB7	hyper	231.5	0.0000
	12	104171621	104171859	NT5DC3	hypo	232.6	0.0000
	6	10400680	10400800	TFAP2A	hyper	50.44	0.0000
	19	15064946	15065141	SLC1A6	hypo	229.3	0.0000
	6	87797830	87797925	CGA	hyper	83.41	0.0000
	10	47169786	47169877	ANXA8	hyper	31.07	0.0000
	11	64323401	64323840	SLC22A11	hyper	42.56	0.0000
	7	29928921	29929023	WIPF3	һуро	19.15	0.0000
	6	31686701	31686920	LY6G6C	hypo	96.38	0.0000
	11	44954481	44954820	TP53I11	hypo	32.12	0.0000
	11	133790161	133791020	IGSF9B	hypo	204.4	0.0000
	9	16964	17166	WASH1	hyper	15.72	0.0000
	19	50713615	50713960	MYH14	hyper	20.14	0.0000
	11	119998121	119998277	TRIM29	hyper	62.24	0.0000
	4	75230859	75231092	EREG	hyper	213	0.0000
	19	52034835	52035110	SIGLEC6	hyper	67.58	0.0000
	7	6661381	6662240	ZNF853	hypo	11.16	0.0000
LPE vs NP	21	44339161	44339401	ERVH48-1	hyper	407.1	0.0000
	6	87804730	87804865	CGA	hyper	283.5	0.0000
	19	2809601	2810488	THOP1	hyper	51.03	0.0000
	14	101200941	101201180	DLK1	hyper	29.01	0.0000
	19	2794761	2794910	THOP1	hyper	15.96	0.0000
	1	186649370	186649559	PTGS2	hyper	19.23	0.0000
	19	43773519	43773715	PSG9	hyper	12.00	0.0000
	20	25011394	25011420	ACSS1	hyper	30.39	0.0000
	15	23261762	23262019	GOLGA8I	hyper	11.02	0.0000
	2	202146601	202146638	CASP8	hypo	197.4	0.0000
	1	40095898	40095980	HEYL	hyper	12.48	0.0000
	19	43766011	43766290	PSG9	hyper	579.9	0.0000
	1	36931643	36931960	CSF3R	hyper	8.06	0.0000
	X	49597127	49597253	PAGE4	hyper	221.5	0.0000
	4	1368881	1369067	UVSSA	hyper	7.78	0.0000
	16	89986241	89986740	MC1R	hyper	7.73	0.0000
	X	132730393	132730627	GPC3	hyper	8.78	0.0000
	7	6661381	6662240	ZNF853	hypo	11.53	0.0000
	4	89744141	89744512	FAM13A	hyper	11.90	0.0000
	1	204199540	204199714	PLEKHA6	hyper	13.14	0.0000
EPE vs LPE	19	43708624	43708766	PSG4	hypo	379.00	0.0000
	19	49560377	49561120	CGB7	hyper	212.20	0.0000
	19	17936961	17937580	JAK3	hypo	20.42	0.0000
	19	15064946	15065141	SLC1A6	hyper	210.10	0.0000
	10	47169786	47169877	ANXA8	hyper	36.46	0.0000
	19	18901370	18901422	COMP	hyper	34.74	0.0000
	19	17462381	17462860	PLVAP	hypo	9.63	0.0000
	3	8794761	8794910	OXTR	hypo	10.92	0.0000
	14	106053890	106054211	DKFZp686016217	hypo	10.12	0.0000
	15	99672881	99673140	SYNM	hypo	7.61	0.0000
	17	74524361	74524693	CYGB	hyper	197.70	0.0000
	12	8988161	8988262	A2ML1	hyper	193.00	0.0000
	10	47167981	47168360	ANXA8	hyper	11.46	0.0000
	12	8988850	8988935	A2ML1	hyper	173.10	0.0000
	19	8429341	8429523	ANGPTL4	hyper	34.16	0.0000
	2	239148301	239148665	HES6	hypo	18.68	0.0000
	3	8808951	8809180	OXTR	hypo	7.73	0.0000
	10	119000583	119000731	SLC18A2	hyper	14.81	0.0000
	15	63346647	63346740	TPM1	hyper	6.63	0.0000
	8	143694781	143695060	ARC	hyper	6.93	0.0000

EPE: Early-onset preeclampsia; NP: Normal pregnancy; LPE: Late-onset preeclampsia.




Figure 3. The consensus clustering and GSVA of m^1A regulators in preeclamptic decidua. (A) Heatmap of consensus clustering of 10 m^1A regulators in PE decidua; (B) The expression levels of 10 m^1A methylation regulators between EPE and LPE (* P < 0.05); (C) Heatmap of GSVA for cluster A in PE and NP decidua; (D) Heatmap of GSVA for cluster B in PE and NP decidua; (E) Heatmap of GSVA for cluster C in PE and NP decidua. GSVA: Gene set variation analysis; PE: Preeclampsia; EPE: Early-onset preeclampsia; LPE: Late-onset preeclampsia; NP: Normal pregnancy.

and nucleotide sugar metabolism, glycosaminoglycan degradation, and galactose metabolism, among others. m¹A cluster B is notably enriched in sulfur metabolism, ascorbate and aldarate metabolism, and tryptophan metabolism, among others (Figure 3D). Meanwhile, m¹A cluster C is significantly enriched in proximal tubule bicarbonate reclamation, alpha linolenic acid metabolism, limonene and pinene degradation, butanoate metabolism, fatty acid metabolism, and beta alanine metabolism, among others (Figure 3E).

Functional annotation for m¹A-related DEGs

A total of 940 m¹A-related DEGs were identified among three m¹A modification patterns (Figure 4A). According to the GO analysis, the m¹A-related DEGs are notably enriched in gly-cosaminoglycan binding, heparan binding, extracellular matrix binding, and others (MF); extracellular region, extracellular space, plasma membrane, and others (CC); and extracellular matrix organization, epidermis development, angiogenesis, and others (BP) (Figure 4B). Additionally, based on the KEGG analysis, the m¹A-related DEGs are significantly enriched in the PI3K-Akt signaling pathway, MAPK signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Ras signaling pathway, and others (Figure 4C).

Conjoint analysis of DMGs and DEGs

The conjoint analysis of DMGs and DEGs in pairwise comparisons was divided into four categories based on

their methylation and expression levels: hypermethylatedupregulated, hypomethylated-downregulated, hypermethylateddownregulated, and hypomethylated-upregulated. The GO analysis of these four categorized DMGs and DEGs is displayed in Table 2.

The comparison between EPE and NP revealed that 356 genes expressed in EPE decidua showed synchronization between m¹A methylation and transcription levels, while 45 genes showed non-synchronization. The differentially hypermethylated mRNAs were significantly involved in downregulated expressed pathways such as base excision repair and Notch signaling pathway. The upregulated expressed pathways included ECM-receptor interaction, PI3K-Akt signaling pathway, focal adhesion, protein digestion and absorption, and amoebiasis. On the other hand, the differentially hypomethylated mRNAs were significantly involved in downregulated expressed pathways, such as hypertrophic cardiomyopathy, dilated cardiomyopathy, focal adhesion, vascular smooth muscle contraction, and ECM-receptor interaction. The upregulated expressed pathways included oxytocin signaling pathway, lipid and atherosclerosis, nucleocytoplasmic transport, relaxin signaling pathway, and estrogen signaling pathway (Table 3).

The comparison between LPE and NP revealed that 144 genes expressed in LPE decidua showed synchronization between $m^{1}A$ methylation and transcription levels, while 62 genes showed non-synchronization. The differentially




Figure 4. The functional annotation of m¹A-related DEGs. (A) Identification of m¹A-related DEGs. The functional annotation of m¹A-related DEGs using GO enrichment analysis (B) and KEGG enrichment analysis (C). DEG: Differentially expressed mRNAs; GO: Gene ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes.

hypermethylated mRNAs were found to be significantly involved in non-homologous end-joining (downregulated expression), autophagy-animal, Fc gamma R-mediated phagocytosis, longevity regulating pathway-multiple species, synaptic vesicle cycle, and EGFR tyrosine kinase inhibitor resistance (upregulated expression). On the other hand, the differentially hypomethylated mRNAs were significantly involved in ABC transporters, synaptic vesicle cycle, TGF- β signaling pathway, and protein digestion and absorption (downregulated expression). Additionally, focal adhesion, ECM-receptor interaction, MAPK signaling pathway, AGE-RAGE signaling pathway in diabetic complications, and amoebiasis were identified as being upregulated (Table 3).

The comparison between EPE and LPE revealed that 218 genes expressed in EPE decidua were synchronized between m^1A methylation and transcription levels, while 50 genes were unsynchronized. The differentially hypermethylated mRNAs were significantly involved in downregulated expression of aldosterone-regulated sodium reabsorption, endocrine and other factor-regulated calcium reabsorption, and steroid hormone biosynthesis. For the upregulated expression, they were involved in ECM-receptor interaction, protein digestion and

absorption, human papillomavirus infection, focal adhesion, and small cell lung cancer. Regarding the differentially hypomethylated mRNAs, they were significantly involved in downregulated expression of vascular smooth muscle contraction, oxytocin signaling pathway, axon guidance, transcriptional misregulation in cancer, and hypertrophic cardiomyopathy. For the upregulated expression, they were involved in non-homologous end-joining, arginine biosynthesis, terpenoid backbone biosynthesis, and thyroid cancer (Table 3).

Validation of external datasets for the differential expression of key $m^1A\mbox{-}related$ DEGs and $m^1A\mbox{-}modulators$

For external validation of the key m¹A-related DEGs, we consulted the GEO dataset, GSE60438, which comprised gene expression data from 60 PE patients and 65 normal samples. We observed significant differences in the mRNA expression of *COLIA2, IGF2, LAMC2, NOS3, SCIN, HSDIIB2, POLM, DES, FLNB,* and *COLI7A1* between PE decidua and NP decidua (Figure S5). These findings further underscore the reliability of our study. Additionally, we also observed significant differences in the mRNA expression of *ALKBH1, ALKBH3, YTHDC1,* and *YTHDF1*

Table 2. The top five significant GO terms of DMGs and DEGs in conjoint analysis

Pairwise comparisons	DMGs methylation-DEGs expression pattern	GO terms	Genes involved	P value	
EPE vs NP	hyper-down	ВР			
		Notch signaling pathway	FOXC1, MAML3, TSPAN14	0.0003	
		Protein localization to plasma membrane	LRP6, DPP6, TSPAN14	0.0006	
		Positive regulation of Notch signaling pathway	MAML3, TSPAN14	0.0007	
		Demethylation	KDM1B, TDG	0.0009	
		Protein localization to cell periphery	LRP6, DPP6, TSPAN14	0.0009	
			CC		
		Tetraspanin-enriched microdomain	TSPAN14	0.0069	
		Wnt signalosome	LRP6	0.0083	
		Centriolar satellite	SDCCAG8	0.0207	
		Nuclear heterochromatin	FOXC1	0.0227	
		Plasma membrane protein complex	LRP6, DPP6	0.0381	
			MF		
		Transcription coregulator activity	FOXC1, MAML3, TDG	0.0056	
		Mismatched DNA binding	TDG	0.0076	
		Chloride ion binding	TDG	0.0076	
		Low-density lipoprotein particle receptor	LRP6	0.0092	
	activity DNA N-glycosylase activity TDG		TDG	0.0099	
	hyper-up		BP		
		Hemidesmosome assembly	COL17A1, ITGB4, LAMC2, LAMB3, KRT14, KRT5, LAMA3	0.0000	
		Epidermis development	KRT24, COL17A1, KRT6A, ERRFI1, DSC3, LAMC2, DSP, FLNB, LAMB3, INHBA, KRT19, KRT5, KRT7,	0.0000	
		Skin development	LAMA3, AGPAT2, PTCH2, KRT8, SFN COMP, COL5A1, KRT24, ITGB4, KRT6A, ERRFI1, DSC3, DSP, FLNB, INHBA, KRT19, KRT14, KRT5,	0.0000	
		Cell-substrate junction	KRT7, PTCH2, KRT8, SFN COL17A1, FN1, ITGB4, LAMC2, LAMB3, KRT14, KRT5, PTK2B, LAMA3	0.0000	
		Cornification	KRT24, KRT6A, DSC3, DSP, KRT19, KRT14, KRT5, KRT7, KRT8	0.0000	
			СС		
		Extracellular matrix	COMP, COL5A1, MMP15, COL17A1, FN1, COL27A1, LAMC2, FBN2, SERPINE2, LAMB3, SERPINE1, LAMA3, PZP, DST, GPC1, COL28A1, TFP12, ADAMTSL4	0.0000	
		Collagen-containing extracellular matrix	COM ^P , COL5A1, COL17A1, FN1, LAMC2, FBN2, SERPIN2, LAMB3, SERPINE1, LAMA3, PZP, DST, GPC1, COL28A1, ADAMTSL4	0.0000	
		Basement membrane	COL5A1, COL17A1, FN1, LAMC2, LAMB3, LAMA3, DST, COL28A1	0.0000	
		Extracellular matrix component	COL5A1, COL27A1, LAMC2, FBN2, LAMB3, LAMA3	0.0000	
		Cell cortex	SCIN, LAMC2, FLNB, SH3BP1, KRT19, PTK2B, DST, FNBP1L, KCNC3	0.0000	
			MF		
		Extracellular matrix structural constituent	COMP, COL5A1, COL17A1, FN1, COL27A1, LAMC2, FBN2, LAMB3, LAMA3, COL28A1, TFP12	0.0000	
		Serine-type endopeptidase inhibitor activity	SPINT2, SERPINE2, SERPINE1, PZP, COL28A1	0.0000	
		Structural constituent of cytoskeleton	KRT6A, DSP, KRT19, KRT14, KRT5	0.0001	
		Extracellular matrix structural	COL5A1, COL17A1, COL27A1, COL28A1	0.0001	
		constituent conferring tensile strength Cell adhesion molecule binding	COMP, COL5A1, FN1, IGF2, DSP, FLNB, DST, FNBP1L, COBLL1, SFN	0.0004	

Table 2. Continued

hypo-down BP Muscle system process TRW2, DES, LMOD2, CNN2, CALD2, ACTG2, KF2, MV19 Muscle contraction TRW2, DES, LMOD2, CNN2, CALD2, ACTG2, KF2, MV19 Negative regulation of smooth muscle cell apoptotic process LRP8, IGF1 Contractile fiber TRW2, DES, LMOD2, SMP02, CALD2, MV19 Structural constituent of muscle TRW2, DES, LMOD2, SMP02, CALD2, ACTG2, MV19 TRW2, DES, LMOD2, SMP02, CALD2, ACTG2, MV19 TRW2, LMOD2, SMP02, CALD2, ACTG2, MV19 Structural constituent of muscle TRW2, LMOD2, SMP02, CALD2, ACTG2, MV19 Tesus homeostatis TRW2, LMOD2, SMP02, CALD2, ACTG2, MV19 Nucleatide biosynthetic process NUPB8, TCCN, NOS3, AAAS, KM0 Tissue homeostatis LDP2, MU16, NOS3, LRRK, NN Correctile most the protein or reduction NUPB8, RCCN, NOS3, AAAS, KM0 Other organism MUPB8, RCCN, NOS3, LRRK, NN Obter org	P value	Genes involved	GO terms	DMGs methylation-DEGs expression pattern	Pairwise comparisons
Muscle system process TPM2 DES, LMODJ, CNNJ, CALDJ, ACTG2, IGFJ, Muscle contraction Muscle contraction TPM2, DES, LMODJ, CNNJ, CALDJ, ACTG2, MVL9 Negative regulation of smooth muscle Cell appottor process LRP6, IGF1 Cellular response to ethanol Positive regulation of givoptic process CC Very Destination of givoptic process CC Actin cytoskeletion TPM2, DES, LMODI, SYMPO2, CALDJ, ACTG2, MYL9 Muscle contractile fiber part TPM2, DES, LMODI, SYMPO2, CALDJ, ACTG2, MYL9 Muscle contractile fiber part TPM2, DES, LMODI, SYMPO2, CALDJ, ACTG2, MYL9 Muscle contractile fiber part TPM2, DES, LMODI, SYMPO2, CALDJ, ACTG2, MYL9 Muscle contractile fiber part TPM2, DES, LMODI, SYMPO2, CALDJ, ACTG2, MYL9 Muscle contractile fiber part TPM2, DES, LMODI, SYMPO2, CALDJ, ACTG2, MYL9 Integrin binding TPM2, DES, LMODI, SYMPO2, CALDJ, ACTG2, MYL9 NUPER, FCR, NOS3, AAAS, KMO NUPER, FCR, NOS3, LARKI Nucleatide biosynthetic process NUPER, FCR, NOS3, LARKI Toxidoreductas actinity, acting		BP		hypo-down	
Muscle contraction smooth muscle cell apoptotic process Cellular response to othand Positive regulation of glycolytic process Cellular response to othand Positive regulation of glycolytic process Cellular response to othand Contractile fiber part Contractile fiber Contractile fiber Cont	0.0000		Muscle system process	21	
Cellular response to ethanol KCNMB2, IP53NP2, 287820, IGF1 CC Myofbril Contractile fiber part TFW2, DES, LMOD1, SWP02, CALD1, MY19 Contractile fiber part TFW2, DES, LMOD1, SWP02, CALD1, MY19 Contractile fiber part TFW2, DES, LMOD1, SWP02, CALD1, MY19 Contractile fiber part TFW2, DES, LMOD1, SWP02, CALD1, ACTG2, MY19 Actin cytoskeleton TFW2, DES, LMOD1, SWP02, CALD1, ACTG2, MY19 Actin cytoskeleton TFW2, DES, LMOD1, SWP02, CALD1, ACTG2, MY19 Contractile fiber part TFW2, DES, LMOD1, SWP02, CALD1, ACTG2, MY19 Contractile fiber part TFW2, DES, LMOD1, SWP02, CALD1, ACTG2, MY19 Contractile fiber part TFW2, DES, LMOD1, SWP02, CALD1, ACTG2, MY19 Constituent Actin binding TFW2, DES, LMOD1, SWP02, CALD1, ACTG2, MY19 Constituent Actin binding TFW2, LMOD1, SWP02, CALD1, ACTG2, MY19 Constituent Actin binding CALD1, MY19 Pype-up P Nucleotide biosynthetic process NuP188, TECR, NOS3, MAS, KMO NuP188, TECR, NOS3, LRRCI NuP188, TECR, NOS3, LRRCI NuP188, FECR, NOS3, LRRCI NuP188, FECR, NOS3, LRRCI NuP188, FECR, NOS3, LRRCI NuP188, RAAS Corboxylic acid biosynthetic process Organic acid biosynthetic process Organic acid biosynthetic process NuP188, RAAS Corboxylic acid biosynthetic process Organic	0.0000 0.0004		Negative regulation of smooth muscle		
CC Myofibril TFW2, DES, LMOD1, SYMP02, CALD1, MY19 Contractile fiber TFW2, DES, LMOD1, SYMP02, CALD1, MY19 Sarcomere TFW2, DES, LMOD1, SYMP02, MY19 Contractile fiber part TFW2, DES, LMOD1, SYMP02, MY19 Actin cytoskeleton TFW2, DES, LMOD1, SYMP02, MY19 Structural constituent of muscle MF Structural constituent of muscle TFW2, DES, LMOD1, SYMP02, MY19 Structural constituent of muscle TFW2, DES, LMOD1, SYMP02, MY19 Structural constituent of muscle TFW2, LMOD1, SYMP02, MY19 Structural constituent of muscle TFW2, DES, LMOD1, SYMP02, MY19 Structural constituent of muscle TFW2, LMOD1, SYMP02, MY19 Mysin binding TFW2, LMOD1, SYMP02, MY19 Mysin binding TFW2, LMOD1, SYMP03, MY19 Mysin binding TFW2, LMOD1, SYMP04, MY19 Mysin binding TFW2, LMOD1, SYMP04, MY19 Mysin binding TFW2, LMOD1, SYMP03, MY19 Mysin binding TFW2, LMOD1, SYMP03, AMX5, MM0 Nucleatide biosynthetic process NUP188, TECR, NOS3, AAAS, KM0 Organic acid biosynthetic process NUP188, AAAS, SM00 Cotadoreductase activity, acting on paire	0.0004 0.0008		Cellular response to ethanol		
Contractile fiber TPM2, DES, LMOD1, SYMP02, CALD1, MV19 Scroomere TPM2, DES, LMOD1, SYMP02, MV19 Contractile fiber part TPM2, DES, LMOD1, SYMP02, MV19 Actin cytoskeleton TPM2, DES, LMOD1, SYMP02, MV19 Actin cytoskeleton TPM2, LMOD1, SYMP02, CALD1, ACTG2, MYL9 Extracellular matrix structural Constituent of muscle TPM2, LMOD1, SYMP02, CALD1, ACTG2, MYL9 Extracellular matrix structural MMF Nucleotide biosynthetic process NUP188, TECR, NOS3, AAAS, KMO Nucleotide biosynthetic process NUP188, PLO27, TECR, AAAS, KMO NUP188, PLO27, TECR, AAAS, KMO NUP188, PLO27, TECR, AAAS, KMO Organic acid biosynthetic process NUP188, PLO27, TECR, AAAS, KMO Organic acid biosynthetic process NUP188, PLO27, TECR, AAAS, KMO NUP188, PLO27, TECR, AAAS, KMO NUP188, AAAS Other organism cell NUP188, AAAS SLC0281, SLC25A29, SLC6A20 Transporter activity Riavin adenine dinucleotide binding NOS3, KMO Adoner, and incorporation or reduction of molecular oxygen, NOQ2(PH as one donors, with incorporation or reduction of molecular oxygen, NOQ2(PH as one donors, with incorporation or reduction of molecular oxygen, NOQ2(PH as one donors, with incorporation or reduction of molecular oxygen, NOQ2(PH as one donors, with incorporation or feduction of molecular oxygen, NOQ2, SLC6A20 activity Flavin adenine dinucleotide binding NOS3, KMO		CC			
Actin cytoskeleton TPM2, DES, LMODJ, SVMP02, ANU9 Actin cytoskeleton TPM2, LMODJ, SVMP02, CALDJ, ACTG2, MYL9 MF Integrin binding VWF, SPP1, ICF1 Structural constituent of muscle TPM2, LMODJ, CNN, CALDJ Actin binding TPM2, LMODJ, CNN, CALDJ Actin binding TPM2, LMODJ, CNN, CALDJ Actin binding TPM2, LMODJ, CNN, CALDJ Mysoin binding CALDJ, MYL9 hypo-up BP Nucleotide biosynthetic process NUP188, TECR, NOS3, AAAS, KMO Nucleotide biosynthetic process NUP188, TECR, NOS3, AAAS, KMO Organic acid biosynthetic process NUP188, PLODZ, TECR, AAAS, KMO Organic acid biosynthetic process NUP188, PLODZ, TECR, AAAS, KMO Organic acid biosynthetic process NUP188, PLODZ, TECR, AAAS, KMO Organic acid biosynthetic process NUP188, PLODZ, TECR, AAAS, KMO Other organism NUP188, AAAS Other organism cell NUP188, AAAS Other organism cell NUP188, AAAS Other organism cell NUP188, AAAS Ordoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen NOS3, KMO	0.0000				
Actin cytoskeleton TPM2, LMODI, SYNP02, CALDI, ACTG2, MYL9 MF Integrin binding VWF, SPP1, IGF1 Structural constituent of muscle TPM2, MYL9 Extractural constituent of muscle TPM2, MYL9 MMRN2, SBSP0N, VWF Constituent Actin binding TPM2, LMODI, SVNP02, CALDI, CALDI MVP188, TECR, NOS3, AAAS, KMO NUP188, TECR, NOS3, AAAS, KMO Nucleotide biosynthetic process NUP188, TECR, NOS3, AAAS, KMO Nucleotide biosynthetic process NUP188, TECR, NOS3, AAAS, KMO Organic acid biosynthetic process NUP188, TECR, NOS3, AAAS, KMO Organic acid biosynthetic process NUP188, TECR, NOS3, AAAS, KMO Organic acid biosynthetic process NUP188, TECR, NOS3, AAAS, KMO Organic acid biosynthetic process NUP188, TECR, NOS3, AAAS, KMO Organic acid biosynthetic process NUP188, AAAS Other organism NUP188, AAAS Other organism cell NUP188, AAAS Oxidoreductase activity, acting on paired MF Oxidoreductase activity, acting on paired NOS3, KMO Oxidoreductase activity, acting on paired MF Oxidoreductase activity, a	0.0000	TPM2, DES, LMOD1, SYNPO2, MYL9			
Integrin binding VWF, SPP1, IGF1 Structural constituent of muscle Extracellular matrix structural Constituent Actin binding TPM2, IMV19 MV19 MV19 Nucleotide biosynthetic process NUP188, FECR, NOS3, AAA5, KMO NUCleotide biosynthetic process Tissue homeostasis LDB2, MUC6, NOS3, LRR1 Carboxylic acid biosynthetic process NUP188, FECR, NOS3, AAA5, KMO Organic acid biosynthetic process NUP188, PLOD2, TECR, AAA5, KMO Carboxylic acid biosynthetic process NUP188, PLOD2, TECR, AAA5, KMO NUP188, FLOD2, TECR, AAA5, KMO Cordinatio acid biosynthetic process NUP188, PLOD2, TECR, AAA5, KMO Carboxylic acid biosynthetic process NUP188, PLOD2, TECR, AAA5, KMO Cordinatio acid biosynthetic process NUP188, PLOD2, TECR, AAA5, KMO Cordinatio acid biosynthetic process NUP188, PLOD2, TECR, AAA5, KMO Cordinatio acid biosynthetic process NUP188, PLOD2, TECR, AAA5, KMO Cordinatio acid biosynthetic process NUP188, PLOD2, TECR, AAA5, KMO NUP188, AAA5 Other organism cell NUP188, AAA5 Cordiorductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAO(P)H as one donor, and incorporation or reduction of molecular oxygen, NAO(P)H as one donor, and incorporation or reduction of molecular oxygen, NAO(P)H as one donor, and incorporation or feduction of molecular oxygen, NAO(P)H as one donor, and incorporation or feduction of molecular oxygen, NAO(P)H as one donor, and incorporation or feduction of molecular oxygen, NAO(P)H as one donor, and incorporation or feduction of molecular oxygen, NAO(P)H as one donor, and incorporation or feduction of molecular oxygen, NAO(P)H as one donor, and incorporation or feduction of molecular oxygen, NAO(P)H as one donor, and incorporation of one atom of oxygen Amino acid transmembrane transporter activity Evs NP hyper-down BP Somatic hypermutation of immunoglobulin gene Somatic hypermutation of immunoglobulin gene Somatic hypermutation of immunoglobulin gene Somatic hypermutation	0.0000 0.0003				
Structural constituent of muscle TPM2, MN19 Extracellular matrix structural MMRN2, SBSPON, VWF constituent Actin binding Myosin binding TPM2, LMOD1, CNN2, CALD1 Myosin binding CALD1, MY19 hypo-up BP Nucleotide biosynthetic process NUP188, TECR, NOS3, AAAS, KMO Nucleotide phosphate biosynthetic NUP188, TECR, NOS3, AAAS, KMO process Tissue homeostasis LDB2, WUC6, NOS3, LRRK1 Carboxylic aid biosynthetic process NUP188, PLOD2, TECR, AAAS, KMO Organic acid biosynthetic process NUP188, PLOD2, TECR, AAAS, KMO C C C Cytoplasmic microtubule PAFAHB1, SNPH Host NUP188, AAAS Other organism NUP188, AAAS Other organism cell NUP188, AAAS Other organism cell NUP188, AAAS Other organic anion transmembrane SLC02B1, SLC25A29, SLC6A20 transporter activity, acting on paired donors, with incorporation or reduction of molecular oxygen NOS3, KMO Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen NOS3, KMO LPE vs NP hyper-down BP Somatic hypermutation of immune following on paired donors fination regencein of sowagen		MF			
Extracellular matrix structural constituent Actin binding MMRN2, SBSPON, VWF hypo-up BP Nucleotide biosynthetic process Nurgest biosynthetic process NUP188, TECR, NOS3, AAAS, KMO Nucleotide biosynthetic process NUP188, TECR, NOS3, AAAS, KMO Tissue homeostasis LDB2, MUC6, NOS3, LRRK1 Carboxylic acid biosynthetic process NUP188, PLCD2, TECR, AAAS, KMO Organic acid biosynthetic process NUP188, PLCD2, TECR, AAAS, KMO Creating CC Cytoplasmic microtubule PAFAHIB1, SNPH Host NUP188, AAAS Other organism NUP188, AAAS Other organism cell NUP188, AAAS Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen PLCD2, NOS3, KMO Organic anio transmembrane donors, mit incorporation or neduction of molecular oxygen, NAD(P)H as one donor, and incorporation or on extortion of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen NOS3, KMO LPE vs NP hyper-down BP Somatic hypermutation of immunoglobulin gene Somatic diversification of immune receptor via somatic in utation Sperm axeometa sembly JCCG	0.0017	VWF, SPP1, IGF1			
Image: space	0.0026				
Myosin binding CALDI, MYL9 hypo-up BP Nucleotide biosynthetic process NUP188, TECR, NO33, AAAS, KMO process LDB2, MUC6, NO33, LRK1 Carboxylic acid biosynthetic process NUP188, TECR, NO33, AAAS, KMO Organic acid biosynthetic process NUP188, PLOD2, TECR, AAAS, KMO Organic acid biosynthetic process NUP188, PLOD2, TECR, AAAS, KMO Organic acid biosynthetic process NUP188, PLOD2, TECR, AAAS, KMO CC Cytoplasmic microtubule PAFAHIB1, SNPH Host cell NUP188, AAAS Other organism NUP188, AAAS Other organism cell NUP188, AAAS Ovidoreductase activity, acting on paired PLOD2, NOS3, KMO Onors, with incorporation or reduction of molecular oxygen Organic anion transmembrane SLC02B1, SLC25A29, SLC6A20 transporter activity NOS3, KMO Onors, with incorporation of one atom of oxygen NOS3, KMO donors, with incorporation of one atom of oxygen NOS3, KMO Doxidoreductase activity, acting on paired NOS3, KMO donor, with incorporation of one atom of oxygen NOS3, KMO	0.0045		constituent		
hypo-up BP Nucleotide biosynthetic process NUP188, TECR, NOS3, AAAS, KMO NUCleotide biosynthetic process NUP188, TECR, NOS3, AAAS, KMO process Tissue homeostasis LDB2, MUC6, NOS3, LRRK1 Carboxylic acid biosynthetic process NUP188, PLOD2, TECR, AAAS, KMO CC Cytoplasmic microtubule PAFAH1B1, SNPH Host NUP188, AAAS Other organism NUP188, AAAS Other organism NUP188, AAAS Other organism cell NUP188, AAAS Other organism cell NUP188, AAAS Other organism cell NUP188, AAAS Other organism cell NUP188, AAAS NUP188, AAAS Other organism cell NUP188, AAAS Other organism cell NUP188, AAAS Other organism cell NUP188, AAAS Other organism cell NUP188, AAAS Charbor of molecular oxygen Organic arion transmembrane SLC0281, SLC25A29, SLC6A20 transporter activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donors, with incorporation of nea atom of oxygen Amino acid transmembrane transporter activity Flavin adenine dinucleotide binding NOS3, KMO LPE vs NP hyper-down BP Somatic diversification of mume receptor via somatic mutation Sperm axoneme assembly /QCG	0.0069 0.0072				
Nucleotide biosynthetic process NUP188, TECR, NOS3, AAAS, KMO Nucleotide phosphate biosynthetic NUP188, TECR, NOS3, AAAS, KMO Process LDB2, MUC6, NOS3, LRRK1 Carboxylic acid biosynthetic process NUP188, PLOD2, TECR, AAAS, KMO Organic acid biosynthetic process NUP188, PLOD2, TECR, AAAS, KMO CC C Cytoplasmic microtubule PAFAH1B1, SNPH Host NUP188, AAAS Other organism NUP188, AAAS Other organism cell NUP188, AAAS Other organism cell NUP188, AAAS Organic acid biosynthetic process NUP188, AAAS Other organism cell NUP188, AAAS Other organism cell NUP188, AAAS Organic anion transmembrane SLC02B1, SLC25A29, SLC6A20 transporter activity, acting on paired NOS3, KMO Oridoreductase activity, acting on paired NOS3, KMO Oridoreductase activity, acting on paired NOS3, KMO Dioreduar oxygen NOS3, KMO Amino acid transmembrane transporter activity SLC25A29, SLC6A20 Amino acid transmembrane transporter activity Flavin adenine dinucleotide binding NOS3, KMO BP Somatic diversification of immune receptor via somatic mutation POLM receptor via somatic mutation Goude	0.0072	· · · · · · · · · · · · · · · · · · ·	Myosin binding	hypo up	
Nucleotide phosphate biosynthetic process NUP188, TECR, NOS3, AAAS, KMO Tissue homeostasis LDB2, MUC6, NOS3, LRRK1 Carboxylic acid biosynthetic process NUP188, PLOD2, TECR, AAAS, KMO Organic acid biosynthetic process NUP188, PLOD2, TECR, AAAS, KMO CC CC Cytoplasmic microtubule PAFAHIB1, SNPH Host cell NUP188, AAAS Other organism NUP188, AAAS Other organism cell NUP188, AAAS Other organic anion transmembrane SLC0281, SLC25A29, SLC6A20 transporter activity NOS3, KMO Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen NOS3, KMO Amino acid transmembrane transporter activity SLC25A29, SLC6A20 LPE vs NP hyper-down BP Somatic hypermutation of immunoglobulin gene Somatic hypersification of immune receptor via so	0.0000			пуро-ар	
Tissue homeostasis LDB2, MUC6, NOS3, LRRK1 Carboxylic acid biosynthetic process NUP188, PLOD2, TECR, AAAS, KMO Organic di biosynthetic process NUP188, PLOD2, TECR, AAAS, KMO CC CC Cytoplasmic microtubule PAFAH1B1, SNPH Host cell NUP188, AAAS Other organism NUP188, AAAS Other organism cell NUP188, AAAS Oxidoreductase activity, acting on paired PLOD2, NOS3, KMO donors, with incorporation or reduction of molecular oxygen SLC02B1, SLC25A29, SLC6A20 Oxidoreductase activity, acting on paired NOS3, KMO Host cell incorporation or reduction of molecular oxygen, NAD(P) H as one NOS3, KMO Dimino acid transmembrane transporter SLC25A29, SLC6A20 Amino acid transmembrane transporter SLC25A29, SLC6A20 Amino acid transmembrane transporter SLC25A29, SLC6A20 Somatic hype	0.0000 0.0000		Nucleotide phosphate biosynthetic		
Organic acid biosynthetic process NUP188, PLOD2, TECR, AAAS, KMO CC Cytoplasmic microtubule PAFAH1B1, SNPH Host NUP188, AAAS Host cell NUP188, AAAS Other organism NUP188, AAAS Other organism cell NUP188, AAAS Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen PLOD2, NOS3, KMO Organic anion transmembrane SLC02B1, SLC25A29, SLC6A20 transporter activity NoVidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen NOS3, KMO Oxidoreductase activity, acting on paired donors, with incorporation or neduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen NOS3, KMO LPE vs NP hyper-down BP Somatic hypermutation of immunoglobulin gene Somatic diversification of immune Sperm axoneme assembly POLM Sperm axoneme assembly IQCG	0.0001	LDB2, MUC6, NOS3, LRRK1	•		
CC Cytoplasmic microtubule PAFAH1B1, SNPH Host NUP188, AAAS Host cell NUP188, AAAS Other organism NUP188, AAAS Other organism cell NUP188, AAAS Other organism cell NUP188, AAAS Oxidoreductase activity, acting on paired PLOD2, NOS3, KMO Oxidoreductase activity, acting on paired Organic anion transmembrane SLC02B1, SLC25A29, SLC6A20 SLC02B1, SLC25A29, SLC6A20 transporter activity Oxidoreductase activity, acting on paired donors, with incorporation or reduction NOS3, KMO Oxidoreductase activity, acting on paired NOS3, KMO donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen Amino acid transmembrane transporter SLC25A29, SLC6A20 activity Flavin adenine dinucleotide binding VOS3, KMO BP LPE vs NP hyper-down BP Somatic hypermutation of POLM immunoglobulin gene Somatic diversification of immune Somatic diversification of immune POLM receptor via somatic mutation Sperm axoneme assembly	0.0001				
Cytoplasmic microtubule PAFAH1B1, SNPH Host NUP188, AAAS Host cell NUP188, AAAS Other organism NUP188, AAAS Other organism cell NUP188, AAAS Other organism cell NUP188, AAAS Other organism cell NUP188, AAAS Oxidoreductase activity, acting on paired PLOD2, NOS3, KMO donors, with incorporation or reduction of molecular oxygen Organic anion transmembrane SLC02B1, SLC25A29, SLC6A20 transporter activity Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one Oxidoreductase activity, acting on paired NOS3, KMO donors, with incorporation of one atom of oxygen SUC25A29, SLC6A20 Amino acid transmembrane transporter SLC25A29, SLC6A20 activity Flavin adenine dinucleotide binding NOS3, KMO LPE vs NP hyper-down BP Somatic hypermutation of POLM immunoglobulin gene Somatic diversification of immune Somatic diversification of immune POLM receptor via somatic mutation	0.0002		Organic acid biosynthetic process		
Host NUP188, AAAS Host cell NUP188, AAAS Other organism NUP188, AAAS Other organism cell NUP188, AAAS Other organism cell NUP188, AAAS Oxidoreductase activity, acting on paired MF Oxidoreductase activity, acting on paired PLDD2, NOS3, KMO donors, with incorporation or reduction of molecular oxygen Organic anion transmembrane SLC02B1, SLC25A29, SLC6A20 transporter activity Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen Organic anion transmembrane SLC02B1, SLC25A29, SLC6A20 transporter activity Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donors, and incorporation of one atom of oxygen Amino acid transmembrane transporter SLC25A29, SLC6A20 activity Flavin adenine dinucleotide binding LPE vs NP hyper-down BP Somatic hypermutation of POLM immunoglobulin gene Somatic diversification of immune Somatic diversification of immune POLM receptor via somatic mutation Sperm axoneme assembly					
Host cell NUP188, AAAS Other organism NUP188, AAAS Other organism cell NUP188, AAAS Oxidoreductase activity, acting on paired MF Oxidoreductase activity, acting on paired PLOD2, NOS3, KMO of molecular oxygen Organic anion transmembrane SLC02B1, SLC25A29, SLC6A20 transporter activity Oxidoreductase activity, acting on paired NOS3, KMO donors, with incorporation or reduction of molecular oxygen NOS3, KMO NOS3, KMO Oxidoreductase activity, acting on paired NOS3, KMO NOS3, KMO donor, and incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen NOS3, KMO LPE vs NP hyper-down BP Somatic transmembrane transporter activity Flavin adenine dinucleotide binding NOS3, KMO LPE vs NP hyper-down BP Somatic hypermutation of pOLM POLM immunoglobulin gene Somatic mutation Somatic mutation Sperm axoneme assembly IQCG	0.0024 0.0030	-			
Other organism cell NUP188, AAAS MF Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen PLOD2, NOS3, KMO Organic anion transmembrane SLC02B1, SLC25A29, SLC6A20 transporter activity Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen NOS3, KMO LPE vs NP hyper-down BP Somatic hypermutation of POLM immunoglobulin gene Somatic diversification of immune Somatic diversification of immune POLM receptor via somatic mutation Sperm axoneme assembly IQCG	0.0030				
MF Oxidoreductase activity, acting on paired PLOD2, NOS3, KMO donors, with incorporation or reduction of molecular oxygen Organic anion transmembrane SLC02B1, SLC25A29, SLC6A20 transporter activity Oxidoreductase activity, acting on paired Oxidoreductase activity, acting on paired NOS3, KMO donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen Amino acid transmembrane transporter SLC25A29, SLC6A20 activity Flavin adenine dinucleotide binding LPE vs NP hyper-down BP Somatic hypermutation of Somatic hypermutation of POLM immunoglobulin gene Somatic diversification of immune Somatic diversification of immune POLM receptor via somatic mutation Sperm axoneme assembly	0.0035	-	Other organism		
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen Organic anion transmembrane PLOD2, NOS3, KMO Organic anion transmembrane SLC02B1, SLC25A29, SLC6A20 transporter activity NOS3, KMO Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen NOS3, KMO Amino acid transmembrane transporter activity SLC25A29, SLC6A20 activity Flavin adenine dinucleotide binding NOS3, KMO LPE vs NP hyper-down BP Somatic hypermutation of immunoglobulin gene Somatic diversification of immune Somatic diversification of immune Sperm axoneme assembly POLM	0.0035	NUP188, AAAS	Other organism cell		
donors, with incorporation or reduction of molecular oxygen Organic anion transmembrane transporter activity Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen Amino acid transmembrane transporter activity Flavin adenine dinucleotide binding NOS3, KMO LPE vs NP hyper-down BP Somatic hypermutation of Somatic hypermutation of Somatic diversification of immune Somatic diversification of immune POLM receptor via somatic mutation Sperm axoneme assembly IQCG		MF			
Organic anion transmembrane SLC02B1, SLC25A29, SLC6A20 transporter activity Oxidoreductase activity, acting on paired NOS3, KMO donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one NOS3, KMO donor, and incorporation of one atom of oxygen Amino acid transmembrane transporter SLC25A29, SLC6A20 Amino acid transmembrane transporter activity Flavin adenine dinucleotide binding NOS3, KMO LPE vs NP hyper-down BP Somatic hypermutation of POLM immunoglobulin gene Somatic diversification of immune POLM somatic diversification of immune POLM receptor via somatic mutation Sperm axoneme assembly IQCG IQCG	0.0006	PLOD2, NOS3, KMO	donors, with incorporation or reduction		
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen NOS3, KMO Amino acid transmembrane transporter activity SLC25A29, SLC6A20 Image: Plavin adenine dinucleotide binding NOS3, KMO LPE vs NP hyper-down Somatic hypermutation of immune somatic diversification of immune somatic diversification of immune somatic diversification of immune sperm axoneme assembly POLM Image: Place somatic diversification of sperm axoneme assembly IQCG	0.0006	SLCO2B1, SLC25A29, SLC6A20	Organic anion transmembrane		
Amino acid transmembrane transporter activity Flavin adenine dinucleotide binding NOS3, KMO LPE vs NP hyper-down BP Somatic hypermutation of POLM immunoglobulin gene Somatic diversification of immune POLM receptor via somatic mutation Sperm axoneme assembly IQCG	0.0007	NOS3, KMO	Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of		
Flavin adenine dinucleotide binding NOS3, KMO LPE vs NP hyper-down BP Somatic hypermutation of POLM immunoglobulin gene Somatic diversification of immune Somatic diversification of immune POLM receptor via somatic mutation Sperm axoneme assembly	0.0021	SLC25A29, SLC6A20	Amino acid transmembrane transporter		
Somatic hypermutation of POLM immunoglobulin gene Somatic diversification of immune POLM receptor via somatic mutation Sperm axoneme assembly IQCG	0.0031	NOS3, KMO	,		
immunoglobulin gene Somatic diversification of immune POLM receptor via somatic mutation Sperm axoneme assembly IQCG		BP		hyper-down	LPE vs NP
Somatic diversification of immunePOLMreceptor via somatic mutationSperm axoneme assemblyIQCG	0.0086	POLM			
Sperm axoneme assembly IQCG	0.0093	POLM	Somatic diversification of immune		
Chaperone cofactor-dependent protein DNAJC7	0.0093	•	Sperm axoneme assembly		
	0.0101	DNAJC7			
refolding snRNA processing INTS8	0.0117	INTS8	0		

Table 2. Continued

Pairwise comparisons	DMGs methylation-DEGs expression pattern	GO terms	Genes involved	P value
-			СС	
		Integrator complex	TNTS8	0.0120
			MF	
		Heat shock protein binding	DNAJC7, IQCG	0.0030
		DNA-directed DNA polymerase activity	POLM	0.0160
		GTP-dependent protein binding	RAPGEF5	0.0167
		Chemokine binding DNA polymerase activity	PLP2	0.0175 0.0242
		DNA polymerase activity	POLM	0.0242
	hyper-up		BP	
		Adherens junction assembly	DLG5, PHLDB2, MMP14, KDR	0.0003
		Regulation of cell junction assembly Phagosome maturation	PHLDB2, RAPGEF2, MMP14, KDR SYT7, UNC13B, ATP6V0A1	0.0003
		Positive regulation of vasculogenesis	RAPGEF2, KDR	0.0002
		Positive regulation of regulated secretory	SYT7, UNC13B, GAB2	0.0005
		pathway		
			СС	
		Extracellular matrix	FBN2, TFPI2, SPOCK2, SERPINB9, MUC4, GPC1, MMP14, PKM	0.0001
		Golgi lumen	FURIN, MUC4, GPC1, MMP14	0.0003
		Early phagosome	SYT7, UNC13B	0.0007
		Phagocytic vesicle	SYT7, UNC13B, ATP6V0A1, UVRAG	0.0008
		Endocytic vesicle	SYT7, RAPGEF2, UNC13B, ATP6V0A1, UVRAG	0.0023
		-	MF	
		Growth factor binding Cadherin binding	IGFBP1, FURIN, GPC1, IGF1R, KDR PHLDB2, TAGLN2, TRIM25, KDR, ASAP1, PKM, CAPZB	0.0000 0.0000
		Cell adhesion molecule binding	PHLDB2, TAGLN2, TRIM25, MMP14, KDR, ASAP1, PKM, CAPZB	0.0002
		Phospholipid binding	SYT7, SCIN, ZCCHC2, RAPGEF2, UNC13B, GAB2, ASAP1	0.0003
		Phosphatidylinositol bisphosphate binding	SYT7, SCIN, GAB2, ASAP1	0.0004
	hypo-down		BP	
		Glutamate secretion	PPFIA3, SLC1A1	0.0003
		Acidic amino acid transport	PPFIA3, SLC1A1	0.0006
		Import across plasma membrane	ABCC9, SLC1A1	0.0007 0.0014
		Dicarboxylic acid transport Acid secretion	PPFIA3, SLC1A1 PPFIA3, SLC1A1	0.0014
			CC	0.0021
				0.0101
		Cell cortex region	PPFIA3	0.0181
		Photoreceptor connecting cilium Presynaptic active zone	LCA5 PPFIA3	0.0210 0.0348
		Ciliary transition zone	LCA5	0.0354
		Potassium channel complex	ABCC9	0.0461
			MF	
		Transforming growth factor beta receptor, cytoplasmic mediator activity	SMAD9	0.0065
		L-glutamate transmembrane transporter activity	SLC1A1	0.0065
		Pseudouridine synthase activity	RPUSD3	0.0065
		Acidic amino acid transmembrane	SLC1A1	0.0065
		transporter activity Glutamate binding	SLC1A1	0.0065

Table 2. Continued

Pairwise comparisons	DMGs methylation-DEGs expression pattern	GO terms	Genes involved	P value	
-	hypo-up	ВР			
		Extracellular matrix organization	ADAM19, NFKB2, COL1A2, FN1	0.0020	
		Post-translation protein modification	LTBP1, FN1, FBXL22, FSTL3	0.0026	
		Extracellular structure organization	ADAM19, NFKB2, COL1A2, FN1	0.0033	
		Protein-DNA complex assembly	RSF1, UBTF, RAD23B	0.0046	
		Cell junction assembly	GPBAR1, FN1, PEAK1	0.0049	
			СС		
		Collagen-containing extracellular matrix	ADAM19, LTBP1, COL1A2, FN1, PSAP	0.0003	
		Extracellular matrix	ADAM19, LTBP1, COL1A2, FN1, PSAP	0.0006	
		Endoplasmic reticulum lumen	LTBP1, COL1A2, FN1, FSTL3	0.0011	
		Extracellular matrix component	LTBP1, COL1A2	0.0022	
		SW1/SNF superfamily-type complex	RSF1, CHD4	0.0046	
			MF		
		Protease binding	COL1A2, FN1, PSAP	0.0011	
		Growth factor binding	FLT1, LTBP1, COL1A2	0.0011	
		Extracellular matrix structural constituent	LTBP1, COL1A2, FN1	0.0024	
		Transmembrane receptor protein kinase activity	FLT1, LTBP1	0.0055	
		Ceramide binding	PSAP	0.0170	
EPE vs LPE	hyper-down	BP			
		Platelet degranulation	CFD, SCCPDH	0.0044	
		Cytoskeletal anchoring at plasma membrane	TLN2	0.0078	
		Regulation of morphogenesis of an epithelium	NTN4, AP2A2	0.0085	
		Bleb assembly	PMP22	0.0086	
		Positive regulation of systemic arterial blood pressure	HSD11B2	0.0093	
			СС		
		Platelet alpha granule lumen	CFD, SCCPDH	0.0013	
		Platelet alpha granule	CFD, SCCPDH	0.0024	
		AP-2 adaptor complex	AP2A2	0.0088	
		Ficolin-1-rich granule	CFD, AP2A2	0.0094	
		Clathrin coat of endocytic vesicle	AP2A2	0.0096	
			MF		
		Phospholipid-translocating ATPase activity	ATP10D	0.0088	
		Carbohydrate: cation symporter activity	SLC45A4	0.0097	
		Solute: proton symporter activity	SLC45A4	0.0097	
		Magnesium ion binding	ATP10D, WEE1	0.0143	
		Laminin binding	NTN4	0.0227	
	hyper-up		BP		
		Hemidesmosome assembly	COL17A1, KRT14, LAMB3, LAMA3	0.0000	
		Cell-substrate junction assembly	COL17A1, KRT14, LAMB3, S100A10, LAMA3, CLASP2	0.0000	
		Epidermis development	COL17A1, KRT14, LAMB3, KRT24, RPSS8, KRT6A, KRT8, PTCH2, LAMA3	0.0000	
		Cornification	KRT14, KRT24, PRSS8, KRT6A, KRT8	0.0000	
		Cell junction assembly	COL17A1, KRT14, LAMB3, S100A10, LAMA3, CLASP2	0.0000	

Table 2. Continued

Pairwise comparisons	DMGs methylation-DEGs expression pattern	GO terms	Genes involved	P value	
•		СС			
		Collagen-containing extracellular matrix	COL17A1, LAMB3, PZP, COMP, S100A10, LAMA3, COL28A1	0.0000	
		Basement membrane	COL17A1, LAMB3, LAMA3, COL28A1	0.0000	
		Extracellular matrix	COL17A1, LAMB3, PZP, COMP, S100A10, LAMA3, COL28A1	0.0000	
		Costamere	AHNAK2, KRT8	0.0006	
		Intermediate filament	KRT14, KRT24, KRT6A, KRT8	0.0007	
			MF		
		Extracellular matrix structural constituent	COL17A1, LAMB3, COMP, LAMA3, COL28A1	0.0000	
		Extracellular matrix structural constituent conferring tensile strength	COL17A1, COL28A1	0.0034	
		Collagen binding	COMP, GP6	0.0074	
		Guanyl-nucleotide exchange factor activity	DOCK5, PSD4, KALRN	0.0074	
		Proton transmembrane transporter activity	SLC9A3, ATP6V1E2	0.0082	
	hypo-down		ВР		
		Muscle system process	MEF2C, CNN1, MYH11, ACTG2, MYL9, DES, OXTR, CALD1, TPM2, DDX39B	0.0000	
		Muscle contraction	CNN1, MYH11, ACTG2, MYL9, DES, OXTR, CALD1, TPM2	0.0000	
		Regulation of development growth	MEF2C, ULK2, MAP18, RBP4, DDX39B, HLX	0.0002	
		Regulation of organ growth	MEF2C, RBP4, DDX39B, HLX	0.0002	
		Regulation of chemokine-mediated signaling pathway	SLIT3, ROBO1	0.0003	
			СС		
		Contractile fiber Actin cytoskeleton	MYH11, MYL9, SYNPO2, DES, CALD1, TPM2 MYH11, ACTG2, PDLIM7, MYL9, SYNPO2, CALD1,	0.0000 0.0000	
		Contractile fiber part	TPM2 MYH11, MYL9, SYNPO2, DES, TPM2	0.0001	
		Myofibril	MYL9, SYNPO2, DES, CALD1, TPM2	0.0001	
		Stress fiber	PDLIM7, MYL9, SYNPO2	0.0004	
			MF		
		Structural constituent of muscle RNA polymerase II distal enhancer	MYH11, MYL9, TPM2 MEF2C, SPI1, FLI1	0.0001 0.0014	
		sequence-specific DNA binding	CNNI ANVUIT CALDI TNCI TDAAD	0 0 0 0 1	
		Actin binding Enhancer sequence-specific DNA binding	CNN1, MYH11, CALD1, TNS1, TPM2 MEF2C, SPI1, FLI1	0.0021 0.0025	
		Enhancer binding	MEF2C, SPI1, FLI1 MEF2C, SPI1, FLI1	0.0025	
	hypo-up		BP		
		Sulfur compound catabolic process	CSPG4, FMOD	0.0012	
		Glycosaminoglycan catabolic process	CSPG4, FMOD	0.0019	
		Aminoglycan catabolic process	CSPG4, FMOD	0.0020	
		Somatic diversification of immune receptors	TCF7, POLM	0.0023	
		Cell redox homeostasis	NOS3, SCO2	0.0024	
			СС		
		Lysosomal lumen	CSPG4, FMOD	0.0041	
		Golgi lumen Vacuolar lumen	CSPG4, FMOD	0.0048 0.0129	
		Vacuolar lumen Integrator complex	CSPG4, FMOD INTS4	0.0129	
		Lamellipodium membrane	CSPG4	0.0152	

Pairwise comparisons	DMGs methylation-DEGs expression pattern	GO terms	Genes involved	<i>P</i> value
			MF	
		FMN binding	NOS3	0.0137
		MAP kinase activity	MAP3K13	0.0210
		DNA-directed DNA polymerase activity	POLM	0.0221
		Protein disulfide oxidoreductase activity	SCO2	0.0221
		Extracellular matrix structural constituent conferring compression resistance	FMOD	0.0221

DMGs: Differentially methylated mRNAs; DEGs: Differentially expressed mRNAs; EPE: Early-onset preeclampsia; LPE: Late-onset preeclampsia; NP: Normal pregnancy; BP: Biological processes; CC: Cellular component; MF: Molecular function.

among 10 m¹A modulators between preeclamptic decidua and normal pregnant decidua (Figure S5).

that are closely associated with essential biological pathways involved in the decidualization process.

Discussion

Accumulated evidence reveals that disorders related to m¹A are widely associated with the pathogenesis of many diseases. To our knowledge, this study is the first to investigate the m¹A landscape in preeclamptic decidua using MeRIP-seq. The results of this study demonstrate distinct m¹A modification profiles in the decidua of PE compared to NP. A total of 3110, 2801, and 2818 DMGs were identified when comparing EPE and NP, LPE and NP, and EPE and LPE, respectively. Further, a combined analysis of MeRIP-seq and RNA-seq data was employed to identify genes associated with the differential expression of methylated m¹A peaks and differentially expressed mRNA levels. In addition, we categorized three m¹A modification patterns based on 10 m¹A regulators. Functional annotation analysis of key PE-related DMGs and m¹A-related DEGs revealed their involvement in decidualization and pathways related to vascular dysfunction. These findings highlight the strong relationship between m¹A methylation and the decidualization process in preeclamptic decidua.

Until now, there has been no consensus on the etiology of PE. Recent research has focused primarily on the early stage of decidualization, which allows for implantation. Human epithelial stroma cells (ESCs) derived from nonpregnant women with a history of sPE showed a lack of differentiation, as indicated by the absence of structural changes and secretory markers. Further, conditioned medium from sPE decidual cells was unable to induce cytotrophoblast invasion [5]. Decidualization is a transient phase of the endometrium that makes it receptive to embryonic signaling and promotes implantation. This process occurs before the embryo reaches the uterine cavity and is driven by ovarian hormones such as estrogen and progesterone, as well as an increase in local cAMP production. The cAMP signaling pathway, activated by progesterone, plays a crucial role in sensitizing HESCs and stimulating the transcriptional activity of the progesterone receptor [18]. Decidualization in HESCs is initiated through the rapid non-genomic ERK/MAPK pathway [19]. In this study, we identified DMGs and DEGs

The Notch signaling mechanism is a highly conserved developmental pathway that is essential for implantation and placentation. In primates, HESCs respond to chorionic gonadotropin and progesterone by activating the Notch receptor 1 (NOTCH1) pathway. NOTCH1 induces the expression of α -smooth muscle actin and positively regulates cytoskeletal remodeling and the initial changes typical of the decidualization process [20]. Dysfunction in both the loss and gain of Notch signaling leads to impairment of endometrial function [21]. The PI3K/serine/threonine protein kinase (Akt) pathway is known to affect the synthesis of decidual markers [22], and inhibition of this pathway could be involved in the decrease in motility of HESCs during decidualization [23]. TGF- β is composed of three isoforms, including TGF-β1, TGF-β2, and TGF-β3. Emerging data demonstrate an important interplay between the TGF- β signaling pathway and decidualization [24]. TGF- β 1 plays an essential role in regulating fetal-maternal immune tolerance during pregnancy [25]. Elevated levels of decidual TGF- β 1 suppress the activation of specific subsets of decidual natural killer cells, which in turn contributes to the uteroplacental pathology associated with the onset of PE [26]. This study revealed that the differentially hypomethylated mRNAs in LPE decidua were significantly involved in the TGF- β signaling pathway, showing downregulated expression compared to NP decidua (Table 3). However, the role of the TGF- β signaling pathway in the pathological development of PE is still highly contradictory and requires further elucidation [27].

Further, maternal vascular dysfunction is another feature of PE that plays a role in its pathogenesis and can persist into the postpartum period [28]. Potential abnormalities include impaired placentation, incomplete spiral artery remodeling, and endothelial damage, which consequently lead to placental ischemia [29]. When placental ischemia occurs, bioactive factors are released into the maternal circulation and cause an imbalance between antiangiogenic soluble fms-like tyrosine kinase-1 and soluble endoglin, and proangiogenic vascular endothelial growth factor (VEGF), placental growth factor (PGF), and TGF- β . These bioactive factors target vascular smooth muscle and impact vascular contraction mechanisms,

Table 3. The top five significant pathways of DMGs and DEGs in conjoint analysis

Pairwise comparisons	DMGs methylation-DEGs expression pattern	Pathway terms	Genes involved	P value
EPE vs NP	hyper-down	Base excision repair Notch signaling pathway	TDG MAML3	0.0201 0.0359
	hyper-up	ECM-receptor interaction PI3K-Akt signaling pathway	COMP, FN1, ITGB4, LAMC2, LAMB3, LAMA3, GP6 COMP, FN1, ITGB4, IGF2, LAMC2, LAMB3, DDIT4,	0.0000
		Focal adhesion	FLT1, RPTOR, LAMA3, NOS3 COMP, FN1, ITGB4, LAMC2, FLNB, LAMB3, FLT1, LAMA3	0.0000
		Protein digestion and absorption	COL5A1, COL17A1, COL27A1, SLC9A3, MME, COL28A1	0.0000
		Amoebiasis	FN1, IL1R2, LAMC2, LAMB3, LAMA3	0.0006
	hypo-down	Hypertrophic cardiomyopathy	ITGA7, TPM2, DES, IGF1	0.0000
		Dilated cardiomyopathy Focal adhesion	ITGA7, TPM2, DES, IGF1	0.0001
		Vascular smooth muscle contraction	ITGA7, VWF, SPP1, IGF1, MYL9 KCNMB1, CALD1, ACTG2, MYL9	0.0002
		ECM-receptor interaction	ITGA7, VWF, SPP1	0.0016
	hypo-up	Oxytocin signaling pathway	NFATC3, GNAO1, NOS3	0.0021
		Lipid and atherosclerosis	NFATC3, NOS3, IRF7	0.0053
		Nucleocytoplasmic transport	NUP188, AAAS	0.0143
		Relaxin signaling pathway Estrogen signaling pathway	GNAO1, NOS3 GNAO1, NOS3	0.0201 0.0227
LPE vs NP	hyper-down	Non-homologous end-joining	POLM	0.0048
	hyper-up	Autophagy-animal	RPTOR, DAPK1, IGF1R, UVRAG	0.0021
	nyper up	Fc gamma R-mediated phagocytosis	SCIN, GAB2, ASAP1	0.0063
		Longevity regulating pathway-multiple species	RPTOR, IGF1R	0.0244
		Synaptic vesicle cycle	UNC13B, P6V0A1	0.0373
		EGFR tyrosine kinase inhibitor resistance	IGF1R, KDR	0.0382
	hypo-down	ABC transporters	ABCC9	0.0219
		Synaptic vesicle cycle	SLC1A1	0.0378
		TGF-beta signaling pathway Protein digestion and absorption	SMAD9 SLC1A1	0.0454 0.0496
	hypo-up	Focal adhesion	FLT1, COL1A2, FN1	0.0035
		ECM-receptor interaction	COL1A2, FN1	0.0083
		MAPK signaling pathway	FLT1, NFKB2, MKNK2	0.0102
		AGE-RAGE signaling pathway in diabetic complications	COL1A2, FN1	0.0107
		Amoebiasis	COL1A2, FN1	0.0111
EPE vs LPE	hyper-down	Aldosterone-regulated sodium reabsorption Endocrine and other factor-regulated	HSD11B2 AP2A2	0.0270 0.0384
		calcium reabsorption Steroid hormone biosynthesis	HSD11B2	0.0441
	hyper-up	ECM-receptor interaction	LAMB3, COMP, LAMA3, GP6	0.0000
	пурег-ир	Protein digestion and absorption	COL17A1, SLC9A3, COL28A1	0.0000
		Human papillomavirus infection	LAMB3, COMP, LAMA3, ATP6V1E2	0.0093
		Focal adhesion	LAMB3, COMP, LAMA3	0.0142
		Small cell lung cancer	LAMB3, LAMA3	0.0231
	hypo-down	Vascular smooth muscle contraction	MYH11, ACTG2, MYL9, CALD1	0.0006
		Oxytocin signaling pathway	MEF2C, MYL9, OXTR	0.0100 0.0157
		Axon guidance Transcriptional misregulation in cancer	MYL9, SLIT3, ROBO1 MEF2C, SPI1, FLI1	0.0157
		Hypertrophic cardiomyopathy	DES, TPM2	0.0285
	hypo-up	Non-homologous end-joining	POLM	0.0159
		Arginine biosynthesis	NOS3	0.0267
		Terpenoid backbone biosynthesis	RCE1	0.0267
		Thyroid cancer	TCF7	0.0445

DMGs: Differentially methylated mRNAs; DEGs: Differentially expressed mRNAs; EPE: Early-onset preeclampsia; LPE: Late-onset preeclampsia; NP: Normal pregnancy.

leading to increased vasoconstriction in PE [30]. This study also revealed that differentially hypomethylated mRNAs in the EPE decidua were significantly involved in downregulated expression of vascular smooth muscle contraction pathways compared to both LPE and NP groups (Table 3).

Additionally, the uterine vascular adaptation to pregnancy is modulated by ovarian hormones, including estrogen and relaxin, which affect both the endothelium and the vascular smooth muscle [31, 32]. This study discovered the differentially hypomethylated mRNAs in EPE decidua were significantly involved in the upregulated expression of pathways, including relaxin signaling pathway and estrogen signaling pathway (Table 3). Relaxin, a peptide hormone secreted by the corpus luteum and circulating during pregnancy, exhibits local expression in decidua cells along with its major receptor, relaxin/insulin-like family peptide receptor 1 (RXFP1) [33]. Several clinical studies have documented a significant change in the levels of estradiol and relaxin during PE [34, 35]. Plenty of evidence demonstrates that estrogen-induced uterine vasodilation in pregnancy is through the estrogen-VEGF-NO pathway [32, 36]. Also, VEGF and PGF are emerging as essential mediators in relaxin-induced vasodilation [37, 38]. Therefore, the disturbance of estrogen signaling pathway will decrease uterine vascular resistance and induce uterine hemodynamic changes which are associated with PE.

Additionally, we have noted that the number of unique m¹A methylated mRNAs in NPs is consistently higher than in both EPE and LPE (Figure 1). This suggests a broader range of m¹A modifications in NPs compared to those with PE, potentially due to altered regulatory mechanisms or stress responses in preeclamptic conditions. Some researchers have utilized m¹A modulators for cancer detection, prognostication, clinical staging, and as targets for drug-based disease treatment [39]. Moreover, in our study, we have observed significant differences in the mRNA expression of ALKBH1, ALKBH3, YTHDC1, and YTHDF1 among 10 m¹A modulators between preeclamptic decidua and normal pregnant decidua through external dataset validation (Figure S5). Therefore, it is imperative to undertake further research and development efforts to refine m¹A modulation patterns in decidualization, enabling their versatile application.

There are clear limitations in this study, including the relatively small sample size for a heterogeneous disease like PE. Additionally, the patients in our study are primarily of Asian ethnicity, which may limit the generalizability of our findings to other populations, such as Caucasian or Sub-Saharan African groups. Furthermore, gestational age differences could contribute to the observed modifications. Although we included pairwise comparisons between normal pregnancies and late-onset preeclamptic cases, which had more comparable gestational ages than early-onset preeclamptic cases, the differences in gestational age between normal and preeclamptic decidua could influence the results. This makes it challenging to distinguish whether the observed modifications are due to the disease state or differences in gestational age and highlights the need for further studies to control for this variable more rigorously.

Conclusion

In summary, the present study has revealed that PE decidua exhibits significantly different mRNA m¹A modification patterns and gene expression profiles. These differences impact various signaling pathways related to decidualization and vascular dysfunction. The distinct m¹A modification patterns observed provide valuable insight into how the process of decidualization and vascular function contribute to the development of PE. These m¹A modification regulators could potentially be used as biomarkers or therapeutic targets for PE, necessitating further investigation.

Conflicts of interest: Authors declare no conflicts of interest.

Funding: This study was supported by the National Key R&D Program of China (2019YFA0802600) and the National Natural Science Foundation of China (32170863 and 31871512) to C. Zhang. Support was also received from grants from the Shanghai Commission of Science and Technology (20DZ2270900) and Open Project of Shandong Provincial Key Laboratory of Reproductive Medicine (SDKL2017018).

Data availability: The data that support the findings of this study are available from the corresponding author upon reasonable request.

Submitted: 27 March 2024 Accepted: 23 June 2024 Published online: 03 July 2024

References

- Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol 2013;170(1):1-7. https://doi.org/10.1016/j. ejogrb.2013.05.005.
- [2] Say L, Chou D, Gemmill A, Tuncalp O, Moller AB, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health 2014;2(6):e323-33. https://doi.org/10.1016/S2214-109X(14)70227-X.
- [3] Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' task force on hypertension in pregnancy. Obstet Gynecol 2013;122(5):1122–31. https://doi.org/10.1097/01.AOG. 0000437382.03963.88.
- [4] Tong J, Zhao W, Lv H, Li WP, Chen ZJ, Zhang C. Transcriptomic profiling in human decidua of severe preeclampsia detected by RNA sequencing. J Cell Biochem 2018;119(1):607-15. https://doi.org/10. 1002/jcb.26221.
- [5] Garrido-Gomez T, Dominguez F, Quinonero A, Diaz-Gimeno P, Kapidzic M, Gormley M, et al. Defective decidualization during and after severe preeclampsia reveals a possible maternal contribution to the etiology. Proc Natl Acad Sci USA 2017;114(40):E8468-E77. https:// doi.org/10.1073/pnas.1706546114.
- [6] Conrad KP, Rabaglino MB, Post Uiterweer ED. Emerging role for dysregulated decidualization in the genesis of preeclampsia. Placenta 2017;60:119–29. https://doi.org/10.1016/j.placenta.2017.06.005.
- [7] Dunn CL, Kelly RW, Critchley HO. Decidualization of the human endometrial stromal cell: an enigmatic transformation. Reprod Biomed Online 2003;7(2):151-61. https://doi.org/10.1016/S1472-6483(10)61745-2.
- [8] Dominissini D, Nachtergaele S, Moshitch-Moshkovitz S, Peer E, Kol N, Ben-Haim MS, et al. The dynamic N(1)-methyladenosine methylome in eukaryotic messenger RNA. Nature 2016;530(7591):441–6. https://doi. org/10.1038/nature16998.
- [9] Anreiter I, Mir Q, Simpson JT, Janga SC, Soller M. New twists in detecting mRNA modification dynamics. Trends Biotechnol 2021;39(1): 72–89. https://doi.org/10.1016/j.tibtech.2020.06.002.

- [10] Zhang C, Jia G. Reversible RNA modification N(1)-methyladenosine (m(1)A) in mRNA and tRNA. Genom Proteom Bioinform 2018;16(3):155-61. https://doi.org/10.1016/j.gpb.2018.03.003.
- [11] Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE, Jaffrey SR. Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near stop codons. Cell 2012;149(7):1635–46. https://doi. org/10.1016/j.cell.2012.05.003.
- [12] Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol 2008;9(9):R137. https://doi.org/10.1186/gb-2008-9-9-r137.
- [13] Shen L, Shao NY, Liu X, Maze I, Feng J, Nestler EJ. diffReps: detecting differential chromatin modification sites from ChIP-seq data with biological replicates. PLoS One 2013;8(6):e65598. https://doi.org/10.1371/ journal.pone.0065598.
- [14] Anders S, Theodor Pyl P, Huber W. HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics 2015;31(2):166-9. https://doi.org/10.1093/bioinformatics/btu638.
- [15] Robinson MD, McCarthy DJ, Smyth GK. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010;26(1):139-40. https://doi.org/10.1093/ bioinformatics/btp616.
- [16] Conway JR, Lex A, Gehlenborg N. UpSetR: an R package for the visualization of intersecting sets and their properties. Bioinformatics 2017;33(18):2938-40. https://doi.org/10.1093/bioinformatics/btx364.
- [17] Bardou P, Mariette J, Escudie F, Djemiel C, Klopp C. jvenn: an interactive Venn diagram viewer. BMC Bioinform 2014;15:293. https://doi. org/10.1186/1471-2105-15-293.
- [18] Brar AK, Frank GR, Kessler CA, Cedars MI, Handwerger S. Progesterone-dependent decidualization of the human endometrium is mediated by cAMP. Endocrine 1997;6(3):301-7. https://doi.org/10. 1007/BF02820507.
- [19] Lee CH, Kim TH, Lee JH, Oh SJ, Yoo J-Y, Kwon HS, et al. Extracellular signal-regulated kinase 1/2 signaling pathway is required for endometrial decidualization in mice and human. PLoS One 2013;8(9):e75282. https://doi.org/10.1371/journal.pone.0075282.
- [20] Afshar Y, Miele L, Fazleabas AT. Notch1 is regulated by chorionic gonadotropin and progesterone in endometrial stromal cells and modulates decidualization in primates. Endocrinology 2012;153(6): 2884-96. https://doi.org/10.1210/en.2011-2122.
- [21] Su RW, Strug MR, Jeong JW, Miele L, Fazleabas AT. Aberrant activation of canonical Notch1 signaling in the mouse uterus decreases progesterone receptor by hypermethylation and leads to infertility. Proc Natl Acad Sci USA 2016;113(8):2300-5. https://doi.org/10.1073/pnas.1520441113.
- [22] Fabi F, Asselin E. Expression, activation, and role of AKT isoforms in the uterus. Reproduction 2014;148(5):R85-95. https://doi.org/10. 1530/REP-14-0270.
- [23] Fabi F, Grenier K, Parent S, Adam P, Tardif L, Leblanc V, et al. Regulation of the PI3K/Akt pathway during decidualization of endometrial stromal cells. PLoS One 2017;12(5):e0177387. https://doi.org/10.1371/ journal.pone.0177387.
- [24] Ni N, Li Q. TGFbeta superfamily signaling and uterine decidualization. Reprod Biol Endocrinol 2017;15(1):84. https://doi.org/10.1186/s12958-017-0303-0.

- [25] Yang D, Dai F, Yuan M, Zheng Y, Liu S, Deng Z, et al. Role of transforming growth factor-betal in regulating fetal-maternal immune tolerance in normal and pathological pregnancy. Front Immunol 2021;12:689181. https://doi.org/10.3389/fimmu.2021.689181.
- [26] Zhang J, Dunk CE, Shynlova O, Caniggia I, Lye SJ. TGFb1 suppresses the activation of distinct dNK subpopulations in preeclampsia. EBioMedicine 2019;39:531–9. https://doi.org/10.1016/j.ebiom.2018.12. 015.
- [27] Chuva de Sousa Lopes SM, Alexdottir MS, Valdimarsdottir G. The TGF β family in human placental development at the fetal-maternal interface. Biomolecules 2020;10(3):453. https://doi.org/10.3390/biom10030453.
- [28] Bakrania BA, Spradley FT, Drummond HA, LaMarca B, Ryan MJ, Granger JP. Preeclampsia: linking placental ischemia with maternal endothelial and vascular dysfunction. Compr Physiol 2020;11(1): 1315–49. https://doi.org/10.1002/cphy.c200008.
- [29] Opichka MA, Rappelt MW, Gutterman DD, Grobe JL, McIntosh JJ. Vascular dysfunction in preeclampsia. Cells 2021;10(11):3055. https://doi. org/10.3390/cells10113055.
- [30] Qu H, Khalil RA. Vascular mechanisms and molecular targets in hypertensive pregnancy and preeclampsia. Am J Physiol Heart Circ Physiol 2020;319(3):H661-H81. https://doi.org/10.1152/ajpheart. 00202.2020.
- [31] Chang K, Lubo Z. Review article: steroid hormones and uterine vascular adaptation to pregnancy. Reprod Sci 2008;15(4):336-48. https:// doi.org/10.1177/1933719108317975.
- [32] Shu C, Han S, Xu P, Wang Y, Cheng T, Hu C. Estrogen and preeclampsia: potential of estrogens as therapeutic agents in preeclampsia. Drug Des Devel Ther 2021;15:2543–50. https://doi.org/10.2147/DDDT. S304316.
- [33] Goldsmith LT, Weiss G. Relaxin in human pregnancy. Ann N Y Acad Sci 2009;1160:130-5. https://doi.org/10.1111/j.1749-6632. 2008.03800.x.
- [34] Berkane N, Liere P, Oudinet JP, Hertig A, Lefevre G, Pluchino N, et al. From pregnancy to preeclampsia: a key role for estrogens. Endocr Rev 2017;38(2):123-44. https://doi.org/10.1210/er.2016-1065.
- [35] Conrad KP. Emerging role of relaxin in the maternal adaptations to normal pregnancy: implications for preeclampsia. Semin Nephrol 2011;31(1):15–32. https://doi.org/10.1016/j.semnephrol.2010.10.003.
- [36] Mandala M. Influence of estrogens on uterine vascular adaptation in normal and preeclamptic pregnancies. Int J Mol Sci 2020;21(7):2592. https://doi.org/10.3390/ijms21072592.
- [37] Segal MS, Sautina L, Li S, Diao Y, Agoulnik AI, Kielczewski J, McGuane JT, et al. Relaxin increases human endothelial progenitor cell NO and migration and vasculogenesis in mice. Blood 2012;119(2):629– 36. https://doi.org/10.1182/blood-2011-04-346007.
- [38] Debrah JE, McGuane JT, Novak J, Rubin JP, Conrad KP. Vascular endothelial and placental growth factors: new players in the slow relaxin vasodilatory pathway. Proceedings of the 5th International Convergence on Relaxin and Related Peptides; Maui (HI): 2008.
- [39] Liu Y, Zhang S, Gao X, Ru Y, Gu X, Hu X. Research progress of N1methyladenosine RNA modification in cancer. Cell Commun Signal 2024;22(1):79. https://doi.org/10.1186/s12964-023-01401-z.

Related articles

- 1. MALAT1 inhibits the Wnt/β-catenin signaling pathway in colon cancer cells and affects cell proliferation and apoptosis Junjun Zhang et al., BJBMS, 2020
- 2. Screening and validation of differentially expressed genes in adipose tissue of patients with obesity and type 2 diabetes mellitus Xuewei Tong et al., Biomol Biomed, 2023
- 3. VIRMA promotes the progression of head and neck squamous cell carcinoma by regulating *UBR5* mRNA and m6A levels Chunyu Zhu et al., Biomol Biomed, 2024
- 4. Exploring autophagy-related prognostic genes of Alzheimer's disease based on pathway crosstalk analysis

Fang Qian et al., BJBMS, 2022

Supplementary data




Figure S1. The GO analysis of DMGs in the EPE vs NP comparison. (A) The top ten significantly enriched BP terms among hypermethylated DMGs; (B) The top ten significantly enriched CC terms of hypermethylated DMGs; (C) The top ten significantly enriched molecular function (MF) terms of hypermethylated DMGs; (D) The top 10 significantly enriched biological process (BP) terms of hypomethylated DMGs; (E) The top 10 significantly enriched cellular component (CC) terms of hypomethylated DMGs; (F) The top 10 significantly enriched molecular function.




Figure S2. The GO analysis of DMGs in the LPE vs NP comparison. (A) The top ten significantly enriched BP terms of hypermethylated DMGs; (B) The top ten significantly enriched CC terms of hypermethylated DMGs; (C) The top ten significantly enriched MF terms of hypermethylated DMGs; (D) The top ten significantly enriched BP terms of hypomethylated DMGs; (E) The top ten significantly enriched CC terms of hypomethylated DMGs; (E) The top ten significantly enriched CC terms of hypomethylated DMGs; (F) The top ten significantly enriched MF terms of hypomethylated DMGs. DMGs: Differentially methylated mRNAs; EPE: Early-onset preeclampsia; NP: Normal pregnancy; GO: Gene ontology; LPE: Late-onset preeclampsia; BP: Biological process; CC: Cellular component; MF: Molecular function.




Figure S3. The GO analysis of DMGs in the EPE vs LPE comparison. (A) The top ten significantly enriched BP terms of hypermethylated DMGs; (B) The top ten significantly enriched CC terms of hypermethylated DMGs; (C) The top ten significantly enriched MF terms of hypermethylated DMGs; (D) The top 10 significantly enriched BP terms of hypomethylated DMGs; (E) The top ten significantly enriched CC terms of hypomethylated DMGs; (F) The top 10 significantly enriched MF terms of hypomethylated DMGs. DMGs: Differentially methylated mRNAs; EPE: Early-onset preeclampsia; LPE: Late-onset preeclampsia; GO: Gene ontology; LPE: Late-onset preeclampsia; CC: Cellular component; MF: Molecular function.




Figure S4. The KEGG pathway analysis of DMGs in pairwise comparison. The top ten significantly enriched pathways of hypermethylated (A1) and hypomethylated (A2) DMGs in EPE vs NP. The top ten significantly enriched pathways of hypermethylated (B1) and hypomethylated (B2) DMGs in in LPE vs NP. The top ten significantly enriched pathways of hypermethylated (C1) and hypomethylated (C2) DMGs in EPE vs LPE. The data shown are the negative log₁₀ (*P* value) within each category. DMGs: Differentially methylated mRNAs; EPE: Early-onset preeclampsia; NP: Normal pregnancy; LPE: Late-onset preeclampsia; KEGG: Kyoto Encyclopedia of Genes and Genomes.




Figure S5. The external validation of the mRNA expression of several key m¹A-related DEGs and m¹A modulators. The significant differences in the expression of *COL1A2*, *IGF2*, *LAMC2*, *NOS3*, *SCIN*, *HSD11B2*, *POLM*, *DES*, *FLNB*, *COL17A1*, *ALKBH1*, *ALKBH3*, *TRMT61B*, *YTHDC1*, and *YTHDF1* between preeclamptic decidua and normal pregnant decidua. m¹A: N¹-methyladenosine; DEG: Differentially expressed mRNAs.